8-K: Ultragenyx Setrusumab Fails Primary Endpoints in OI Studies

Ultragenyx Pharmaceutical Inc. announced that its Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta did not meet primary endpoints for fracture rate reduction, despite showing improvements in bone mineral density.

Summary

• Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI) did not achieve statistical significance for their primary endpoints.
• Primary endpoints were the reduction in annualized clinical fracture rate compared to placebo in the Orbit study and bisphosphonates in the Cosmic study.
• Both studies achieved secondary endpoints, demonstrating statistically significant improvements in bone mineral density (BMD) against their respective comparators.
• The safety profile of setrusumab remained unchanged across both studies.
• The company is conducting additional analyses on the data and plans to evaluate and implement significant expense reductions.

Sentiment

Score: 3

Explanation: Significant setback due to the failure of primary endpoints for a key late-stage pipeline asset. While secondary endpoints showed some positive data and the safety profile remained unchanged, the inability to demonstrate a statistically significant reduction in fracture rates is a major negative. Planned expense reductions further indicate financial pressure and strategic re-evaluation.

Positives

• Setrusumab demonstrated statistically significant and substantial improvements in bone mineral density (BMD) in both the Orbit and Cosmic studies.
• No change in the safety profile of setrusumab was observed, indicating continued tolerability.

Negatives

• Neither the Orbit nor Cosmic Phase 3 studies achieved statistical significance for their primary endpoints of reducing annualized clinical fracture rates.
• In the Orbit study, observed BMD improvements were not accompanied by a corresponding reduction in fracture rates, partly attributed to a low fracture rate in the placebo group.
• In the pediatric Cosmic study, while BMD improvements were associated with a reduction in annualized fracture rate, this reduction did not meet statistical significance.
• The company plans to implement significant expense reductions, indicating a negative financial impact and strategic re-evaluation following the trial results.

Risks

• Uncertainty of clinical drug development and the unpredictability and lengthy process for obtaining regulatory approvals.
• Ability to successfully develop UX143.
• Ability to achieve projected development goals in expected timeframes.
• Risk that results from earlier studies may not be predictive of future study results.
• Risks related to adverse side effects.
• Risks related to reliance on third-party partners to conduct certain activities on the company's behalf.
• Potential for any license or collaboration agreement, including the collaboration agreement with Mereo BioPharma Group plc, to be terminated.
• Smaller than anticipated market opportunities for products and product candidates.
• Manufacturing risks.
• Competition from other therapies or products.
• Matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations.
• Impact on future operating results and financial performance.
• Timing of clinical trial activities and reporting results from same.
• Availability or commercial potential of products and drug candidates.

Future Outlook

The company is conducting additional analyses on the data across both studies, including on other bone health and clinical endpoints beyond fractures, to assess next steps for the setrusumab program. Additionally, the company plans to evaluate its planned operations and promptly define and implement significant expense reductions.

Management Comments

• Management is conducting additional analyses on the data across both studies, including on other bone health and clinical endpoints beyond fractures, to assess next steps for the program given the totality of these data.
• Management is evaluating planned operations and will promptly define and implement significant expense reductions.

Industry Context

The failure of a late-stage clinical trial for a rare disease drug like setrusumab in Osteogenesis Imperfecta is a significant event in the biotechnology sector. It highlights the inherent risks in drug development, particularly for conditions with complex pathologies. While improvements in bone mineral density were observed, the inability to achieve statistical significance in fracture rate reduction against established comparators like bisphosphonates, or even placebo in one study, suggests a challenge in demonstrating a clear clinical benefit that would support regulatory approval and market adoption. This outcome could lead to increased scrutiny on other pipeline assets for companies operating in the rare disease space.

Comparison to Industry Standards

• Results indicate that setrusumab did not achieve statistical significance in reducing annualized clinical fracture rates when compared to placebo in the Orbit study or bisphosphonates in the Cosmic study.
• While improvements in bone mineral density were observed, the lack of a corresponding statistically significant reduction in fractures, especially against bisphosphonates which are a standard treatment, suggests that setrusumab did not demonstrate a superior or sufficiently differentiated clinical outcome on the primary endpoint compared to existing or non-interventional approaches.

Stakeholder Impact

• Shareholders: Likely negative impact due to the failure of primary endpoints for a key pipeline asset, potential for stock price decline, and planned expense reductions.
• Patients (OI community): Disappointment as a potential new treatment for fracture reduction did not meet its primary goal, though BMD improvements were observed.
• Employees: Potential for job reductions due to planned significant expense reductions.
• Partners (Mereo BioPharma Group plc): Potential impact on their collaboration agreement and future prospects for setrusumab.

Next Steps

• Conduct additional analyses on the data across both studies, including on other bone health and clinical endpoints beyond fractures.
• Assess next steps for the setrusumab program.
• Evaluate planned operations and promptly define and implement significant expense reductions.

Key Dates

Recommendation

The failure of setrusumab to meet its primary endpoints in both Phase 3 studies for Osteogenesis Imperfecta represents a significant setback for Ultragenyx's pipeline. While secondary endpoints related to bone mineral density showed improvement and the safety profile remained unchanged, the inability to demonstrate a statistically significant reduction in fracture rates, especially against placebo and bisphosphonates, severely diminishes the drug's commercial viability and regulatory path. The company's announcement of significant expense reductions further signals financial strain and a re-evaluation of its strategic priorities. This outcome is likely to lead to a substantial negative re-rating of the stock, warranting a 'sell' recommendation.

Keywords

Ultragenyx, setrusumab, UX143, Osteogenesis Imperfecta, OI, Phase 3, clinical trial, fracture rate, bone mineral density, biotechnology, pharmaceuticals